Eris Lifesciences Makes Significant Investments in Dermatology, Injectables, and Biologics, Aims for EU-CDMO Business Expansion

Eris Lifesciences, one of the top-20 Indian pharmaceutical companies, has made strategic acquisitions amounting to INR 3,900+ crore over FY23-FY25. The company has entered dermatology, injectables, and biologics sectors through these acquisitions. Eris BioNxt, Reddy's, Levim, Lifetech, and Nephro & Derma Biocon are some of the notable acquisitions. The company's international business is marketed in over 70 countries, and it has a wide range of manufacturing capabilities. The EU-CDMO business is expected to start contributing significantly to revenue from FY27. The total investment includes INR 1,265 crore in FY23 and INR 2,640+ crore during Nov '23 - Dec ‘24.